Todd Darmody, MD
Endocrinology, Diabetes & Metabolism · Galion, OHNPI 1225007545
Payments from drug & device makers
Across 66 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$151
- AstraZeneca$139
- Insulet Corporation$96
- Medtronic$77
- Merck$58
- Johnson & Johnson$55
- plus $407 from 16 others
What the payments were for
- Food & beverage$96298%
- Education$212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $151 |
| AstraZeneca(2 entities) | 6 | $139 |
| Insulet Corporation | 4 | $96 |
| Medtronic | 4 | $77 |
| Merck | 4 | $58 |
| Johnson & Johnson | 4 | $55 |
| BETA Bionics, Inc. | 3 | $53 |
| Amgen | 4 | $53 |
| Novo Nordisk | 3 | $42 |
| Shire North American Group Inc | 3 | $39 |
| Tandem Diabetes Care, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| GSK | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $18 |
| Lifescan, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$983 in reported general payments places this provider in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 383 | $463,467 |
| Humalog Kwikpen U-200Insulin Lispro | 111 | $342,853 |
| MounjaroTirzepatide | 234 | $288,019 |
| TrulicityDulaglutide | 201 | $251,567 |
| JardianceEmpagliflozin | 189 | $199,882 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 197 | $151,625 |
| Tresiba Flextouch U-200Insulin Degludec | 86 | $80,912 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $49,166 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $40,792 |
| FarxigaDapagliflozin Propanediol | 33 | $33,269 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $27,916 |
| Novolog FlexpenInsulin Aspart | 83 | $26,569 |
| FiaspInsulin Aspart (Niacinamide) | 25 | $24,213 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 23 | $21,531 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 117 | $20,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $151 | $575,669601 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $42 | $498,298438 claims |
| Boehringer IngelheimJardiance | $24 | $199,882189 claims |
| AstraZenecaFarxiga | $139 | $33,26933 claims |
| MerckJanumet Xr | $58 | $12,93617 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $2,66916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Galion
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
- John PaesWesterville$671K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.